The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Dipeptide Peptidase 4 Inhibitors Market Over The 2026–2030 Period?
The dipeptide peptidase 4 inhibitors market has shown consistent expansion over recent years. Its value is expected to rise from $11.81 billion in 2025 to $12.39 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.0%. This historical growth can be attributed to factors like the increasing worldwide occurrence of type 2 diabetes, the necessity for glucose-reducing treatments with minimal hypoglycemia risk, the widespread clinical acceptance of therapies based on incretin, the availability of numerous branded DPP-4 inhibitors, and the expansion of diabetes management in outpatient settings.
The dipeptide peptidase 4 inhibitors market is anticipated to experience consistent expansion over the upcoming years. By 2030, its value is projected to reach $14.78 billion, achieving a compound annual growth rate (CAGR) of 4.5%. This expansion during the projection period stems from a surging worldwide diabetic population, greater uptake of combination diabetes treatments, an increased emphasis on convenient oral medications for patients, broadened availability of diabetes care in developing economies, and persistent need for economical glycemic management solutions. Key tendencies observed within this timeframe encompass the continued application of dpp-4 inhibitors as supplementary treatment for type 2 diabetes, a rising inclination towards oral antidiabetic drugs, more frequent prescription of dpp-4 inhibitors for older diabetic individuals, heightened interest in fixed-dose combination treatments, and a gradual transition towards generic dpp-4 inhibitor versions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15791&type=smp
Which Major Factors Are Driving The Expansion Of The Dipeptide Peptidase 4 Inhibitors Market?
The expanding incidence of diabetes is projected to fuel the growth of the dipeptide peptidase 4 inhibitors market. Diabetes is a chronic health condition impacting how the body metabolizes glucose (sugar), which is a vital energy source for the body’s cells. The increase in diabetes cases is primarily attributed to the widespread adoption of sedentary lifestyles and unhealthy eating habits in contemporary societies. Dipeptidyl peptidase 4 inhibitors are utilized in diabetes management to enhance glycemic control by inhibiting the degradation of incretin hormones. For instance, in 2024, the International Diabetes Federation, a Belgium-based health organization, reported that 537 million adults (1 in 10) were living with diabetes in 2021, a number expected to rise to 643 million by 2030 and 783 million by 2045. Consequently, the escalating prevalence of diabetes drives the dipeptide peptidase 4 inhibitors market.
How Is The Dipeptide Peptidase 4 Inhibitors Market Segmented Across Key Categories?
The dipeptide peptidase 4 inhibitors market covered in this report is segmented –
1) By Type: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels
3) By Application: Type 2 Diabetes, Gestational Diabetes, Metabolic Syndrome, Other Applications
Subsegments:
1) By Sitagliptin: Branded Sitagliptin, Generic Sitagliptin, Sitagliptin Monotherapy, Sitagliptin Combination Therapy
2) By Saxagliptin: Branded Saxagliptin, Generic Saxagliptin, Saxagliptin Monotherapy, Saxagliptin Combination Therapy
3) By Linagliptin: Branded Linagliptin, Generic Linagliptin, Linagliptin Monotherapy, Linagliptin Combination Therapy
4) By Alogliptin: Branded Alogliptin, Generic Alogliptin, Alogliptin Monotherapy, Alogliptin Combination Therapy
5) By Vildagliptin: Branded Vildagliptin, Generic Vildagliptin, Vildagliptin Monotherapy, Vildagliptin Combination Therapy
6) By Other Types: Teneligliptin, Anagliptin, Gemigliptin, Trelagliptin
Who Are The Dominant Players Shaping The Dipeptide Peptidase 4 Inhibitors Market Landscape?
Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd
Read the full dipeptide peptidase 4 inhibitors market report here:
Which Region Currently Holds The Largest Share Of The Dipeptide Peptidase 4 Inhibitors Market?
Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Dipeptide Peptidase 4 Inhibitors Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15791&type=smp
Browse Through More Reports Similar to the Global Dipeptide Peptidase 4 Inhibitors Market 2026, By The Business Research Company
Dipeptide Peptidase 4 Inhibitors Market Report 2026
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Proteasome Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model